Latest News and Press Releases
Want to stay updated on the latest news?
-
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Aug. 08, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
-
– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance – – Intravitreal Diabetic Macular Edema Phase 2 On Track to Initiate in 2017 – CAMBRIDGE,...
-
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, June 01, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
-
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, May 15, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
-
– Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for HAE –– Intravitreal DME Program Remains on Track for Phase 2 in 2017 –– Company Expects to be Well-Funded Through...
-
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, March 09, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
-
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Nov. 29, 2016 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
-
—Combined company renamed KalVista Pharmaceuticals, Inc., listed on Nasdaq with ticker “KALV” — —Continued focus on development of protease inhibitors with multiple molecules for oral treatment of...
-
SALISBURY, United Kingdom and PALO ALTO, Calif., June 22, 2016 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals Ltd. (“KalVista”), a privately held biopharmaceutical company, and Carbylan Therapeutics,...